Our partner is focused on developing a potent and long-acting monoclonal antibody plasma kallikrein inhibitor, as the potential best-in-class and most patient-friendly prophylactic treatment option for the prevention of attacks in patients affected by hereditary angioedema.

This critical hire led biophysical characterization and functional screening efforts for our partner’s growing antibody therapeutics pipeline. This hire also shaped the overall direction of the Bioassays group. They were also responsible for developing, implementing, and managing a broad range of assays in close relationships with various CRO partners.